Research Synthesis: Longevity vitamin

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Re-extract and re-code directional signals per source and per outcome class so the Findings Map reflects what each cited study actually reports (e.g., Katsube 2024 positive on lifespan/frailty/cognition in mice; Meng 2025 inverse association for dementia risk; Cheah 2026 lower serum ET in AMD). The uniform-null coding is a pipeline artifact, not a finding, and must be corrected.
2. Add an explicit Tensions and Gaps section that names the real disagreements: animal/mechanistic positive signals vs. absence of direct human RCTs; observational dose-response in older adults (Meng 2025) vs. lack of interventional replication; off-topic bioprocess and bibliometric sources vs. clinical relevance; heterogeneity of populations, doses, and endpoints.
3. Remove or clearly segregate off-topic sources (Liu 2026, Wang 2025, Yu 2020, Fu 2025, Villalain 2025) from the clinical-outcome evidence map, or explicitly justify their inclusion as boundary/methods context rather than efficacy evidence.
4. Reconcile the '0 cross-study disagreements' claim with the actual heterogeneity in the bundle, or remove the count and replace it with a substantive description of agreement/disagreement patterns.
5. Provide full source attribution for the Evidence Landscape recommendations (e.g., Cruz-Jentoft 2019 EWGSOP2 cutoffs are not in the bundle; add the source or remove the specific cutoff reference) and ensure the recommended RCT design is presented as a suggested next step grounded in the cited evidence, not as a derived clinical guideline.
6. Clarify the admission funnel arithmetic and define the relationship between 'partial-only', 'mixed partial-or-none', and 'strict high-confidence' categories so the inclusion logic is auditable.

Major issues

• The Findings Map uniformly codes every domain as 'no extracted directional signal' (null=12, null=3, null=2, etc.), yet the source bundle contains multiple primary studies reporting positive directional effects (e.g., Katsube 2024 lifespan extension, Meng 2025 dose-response for dementia risk, Cheah 2026 lower serum ET in AMD patients, Roda 2022/2023 locomotor and cognitive improvements). The null coding appears to be an extraction/pipeline artifact, not a faithful representation of the cited evidence. This is a material source-grounding failure and a collapse of the landscape into a uniform null that contradicts the bundle.
• The Evidence Landscape paragraph and Findings Map claim '0 cross-study disagreements' and '0 non-orthogonal tension(s)', which is implausible given the corpus mixes positive mechanistic/animal findings, null or limited clinical findings, and a bibliometric/production-engineering set (Liu 2026, Wang 2025, Yu 2020) that is off-topic for clinical efficacy. Forcing a 0-disagreement count suppresses real heterogeneity.
• Tensions and Gaps section is generic and does not surface the specific contradictions (e.g., strong animal lifespan data vs. absence of direct human RCTs; positive Hisayama observational dose-response vs. no interventional hard-endpoint evidence; inclusion of microbial-fermentation papers as 'longevity' evidence).
• The manuscript admits to an evidence-role imbalance (0 direct clinical sources) yet still classifies many source rows as if they inform clinical outcomes (e.g., Catalase/sarcopenia cutoffs cited from Cruz-Jentoft 2019 without that source in the bundle; references to Meng 2025 and Suzuki 2025 p-values appear in the Evidence Landscape prose but the bundle provides partial excerpts only).

Minor issues

• The funnel table arithmetic is opaque: 114 + 30 + 142 + 52 ≠ 170 source candidates as labeled, and 'Mixed partial-or-none' and 'Partial-only' are described as audit buckets, leaving the actual inclusion logic unclear.
• Several admitted sources are off-topic for a clinical longevity evidence map (Liu 2026, Wang 2025, Yu 2020 are microbial fermentation/bioprocess engineering; Fu 2025 is bibliometric; Villalain 2025 is a membrane biophysics MD study). Including them inflates claim counts without contributing to outcome-class signals.
• The 'Outcome-class note' defines Contextual Adjacent Evidence as not pooled with direct outcome evidence, but 12/22 sources fall into this class and effectively carry the entire evidence map, so the distinction functions as a label rather than a substantive separation.
• The Evidence Landscape recommends a specific RCT design (EWGSOP2 cutoffs, chronic ergothioneine dose approximating rodent exposure) that goes beyond the cited evidence and reads as an editorialized next-step rather than a faithful mapping.
• AI-use disclosure and accountability section reads as self-certification language and does not contribute evidence to the map.

Reviewer note

This evidence map on ergothioneine ('Longevity vitamin') has a credible scope and a well-described search protocol, and it correctly avoids a single causal/policy conclusion. However, the core of the manuscript — the Findings Map — is not a faithful representation of the source bundle. Every domain is coded as 'no extracted directional signal' (null=12, null=3, null=2, null=2, null=2, null=1), while the cited primary studies clearly report positive directional effects in animal models (Katsube 2024 lifespan and frailty; Roda 2022/2023 locomotor and cognitive improvements; Cadile 2025 SMA phenotype), inverse observational associations in humans (Meng 2025 dementia risk; Cheah 2026 AMD serum levels; Suzuki 2025 dietary correlates), and mechanistic support (Cao 2026, Tng 2026, Harasym 2025, Gede 2025). The uniform-null coding is a pipeline/classification artifact, not a finding, and it collapses the landscape into an unsupported 'no signal anywhere' map that contradicts the very bundle it cites. The '0 cross-study disagreements' claim compounds the problem by forcing artificial consensus onto a corpus that spans off-topic bioprocess engineering, bibliometrics, mechanistic MD, animal aging, and human observational studies. The Tensions and Gaps section is generic and does not name the real contradictions (animal positive vs. no direct human RCT; observational dose-response vs. absent interventional replication; off-topic sources mixed with clinical sources). Because the Findings Map misrepresents the cited evidence, claim_support is partially_supported at best and the map's stated conclusion that the evidence is 'bounded' rests on extraction errors rather than on the actual literature. The manuscript is structurally an evidence map but functionally collapses heterogeneity into a uniform null, which is precisely the failure mode the evidence-map review is designed to flag. The work is salvageable with bounded edits: re-code the directional signals, re-segregate off-topic sources, surface real tensions, and reconcile the admission funnel. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis